Losartan treatment protects retinal ganglion cells and alters scleral remodeling in experimental glaucoma

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Quigley, Harry A ^a   Pitha, Ian F ^a   Welsbie, Derek S ^a   Nguyen, Cathy ^b   Steinhart, Matthew R ^a   Nguyen, Thao D ^a   Pease, Mary Ellen ^a   Oglesby, Ericka N ^a   Berlinicke, Cynthia A ^a   Mitchell, Katherine L ^a   Kim, Jessica ^a   Jefferys, Joan J ^a   Kimball, Elizabeth C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; BETA TUBULIN; ENALAPRIL; LOSARTAN; SPIRONOLACTONE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXIAL CHANGE; BLOOD PRESSURE; CELL DAMAGE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GLAUCOMA; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MEASUREMENT; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; RETINA GANGLION CELL; RETINAL THICKNESS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERA; SCLERA DISEASE; SCLERAL THICKNESS; SIGNAL TRANSDUCTION; SURVIVAL RATE; THICKNESS; VISUAL SYSTEM PARAMETERS; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUMAN; OPTIC DISK; PATHOLOGY; RETINA;

ANIMALS; DISEASE MODELS, ANIMAL; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LOSARTAN; MICE; NEUROPROTECTIVE AGENTS; OPTIC DISK; RETINA; RETINAL GANGLION CELLS; SCLERA;

EID: 84949575499     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141137     Document Type: Article

References (82)

1. Quigley HA, Broman A. The number of persons with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:151-156.
2. Anderson DR, Hendrickson A. Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. Invest Ophthalmol. 1974; 13:771-83. PMID: 4137635
3. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981; 99:635-49. PMID: 6164357
4. Norman RE, Flanagan JG, Sigal IA, Rausch SMK, Terinegg I, Ethier CR. Finite element modeling of the human sclera: Influence on optic nerve head biomechanics and connections with glaucoma. Exp Eye Res. 2011; 93:4-12. doi: 10.1016/j.exer.2010.09.014 PMID: 20883693
5. Sigal IA, Yang H, Roberts MD, Burgoyne CF, Downs JC. IOP-induced lamina cribrosa displacement and scleral canal expansion: An analysis of factor interactions using parameterized eye-specific models. Invest Ophthalmol Vis Sci. 2011; 52:1896-1907. doi: 10.1167/iovs.10-5500 PMID: 20881292
6. Grytz R, Fazio MA, Girard MJA, Libertiaux V, Brunoc L, Gardiner S, et al. Material properties of the posterior human sclera. J Mech Behav Biomed Mater. 2014; 29:602-617. doi: 10.1016/j.jmbbm.2013.03. 027 PMID: 23684352
7. Boland MV, Quigley HA. Risk factors and open-angle glaucoma: concepts and applications. J Glaucoma 2007; 16:406-18. PMID: 17571004
8. Hommer A, Fuchsjäger-Mayrl G, Resch H, Vass C, Garhofer G, Schmetterer L. Estimation of ocular rigidity based on measurement of pulse amplitude using pneumotonometry and fundus pulse using laser interferometry in glaucoma. Invest Ophthalmol Vis Sci. 2008; 49:4046-50. doi: 10.1167/iovs.07- 1342 PMID: 18487379
9. Coudrillier B, Tian J, Alexander S, Myers KM, Quigley HA, Nguyen TD. Biomechanics of the human posterior sclera: age- and glaucoma-related changes measured using inflation testing. Invest Ophthalmol Vis Sci. 2012; 53:1714-28 doi: 10.1167/iovs.11-8009 PMID: 22395883
10. Pijanka JK, Coudrillier B, Ziegler K, Sorensen, Meek KM, Nguyen TD, et al. Quantitative mapping of collagen fiber orientation in non-glaucoma and glaucoma posterior human scleras. Invest Ophthalmol Vis Sci. 2012; 53:5258-70. doi: 10.1167/iovs.12-9705 PMID: 22786908
11. Cone FE, Gelman SE, Son JL, Pease ME, Quigley HA. Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection. Exp Eye Res. 2010; 91:415-24. doi: 10.1016/j.exer.2010.06.018 PMID: 20599961
12. Nguyen C, Cone FE, Nguyen TD, Coudrillier B, Pease ME, Steinhart MR, et al. Studies of scleral biomechanical behavior related to susceptibility for retinal ganglion cell loss in experimental mouse glaucoma. Invest Ophthalmol Vis Sci. 2013; 54:1767-80. doi: 10.1167/iovs.12-10952 PMID: 23404116
13. Cone-Kimball E, Nguyen C, Oglesby EN, Pease ME, Steinhart MR, Quigley HA. Scleral structural alterations associated with chronic experimental intraocular pressure elevation in mice. Mol Vis. 2013; 19:2023-39. PMID: 24146537
14. Pease ME, Oglesby EN, Cone-Kimball E, Jefferys JL, Steinhart MR, Kim AJ, et al. Scleral permeability varies by mouse strain and is decreased by chronic experimental glaucoma. Invest Ophthalmol Vis Sci. 2014; 55:2564-73. doi: 10.1167/iovs.13-13327 PMID: 24557355
15. Oglesby E, Tezel G, Cone-Kimball E, Steinhart MR, Jefferys J, Pease, et al. Molecular and biochemical mechanisms of glaucoma. Invest Ophthalmol Vis Sci. (ARVO abstracts), 2014; May 8, 2014, Program Number: 5693.
16. Steinhart MR, Cone FE, Nguyen C, Nguyen TD, Pease ME, Puk O, et al. Mice with an induced mutation in collagen 8A2 develop larger eyes and are resistant to retinal ganglion cell damage in an experimental glaucoma model. Mol Vis. 2012; 18:1093-106. PMID: 22701298
17. Kimball EC, Nguyen C, Steinhart MR, Nguyen T, Pease ME, Oglesby EN, et al. Experimental scleral cross-linking increases glaucoma damage in a mouse model. Exp Eye Res. 2014; 128:129-40. doi: 10. 1016/j.exer.2014.08.016 PMID: 25285424
18. Sethi A, Mao W, Wordinger RJ, Clark AF. Transforming growth factor-β induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011; 52:5240-5250. doi: 10.1167/iovs.11-7287 PMID: 21546528
19. Johnson EC, Cepurna WO, Doser TA, Morrison JC. Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2007; 48:3161-77. PMID: 17591886
20. Pena JDO, Taylor AW, Ricard CS, Vidal I, Hernandez MR. Transforming growth factor isoforms in human optic nerve heads. Br J Ophthalmol 1999; 83:209-18. PMID: 10396201
21. Danser AHJ, Batenburg WW, van den Meiracker AH, Danilov SM. ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? Pharmacol Ther. 2007; 113:607-618. PMID: 17257685
22. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGFbeta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003; 33:407-11. PMID: 12598898
23. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004; 114:1586-92. PMID: 15546004
24. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312:117-21. PMID: 16601194
25. Yang H, Hirooka K, Fukuda K, Shiraga F. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest Ophthalmol Vis Sci. 2009; 50:5800-4. doi: 10.1167/iovs.09-3678 PMID: 19608537
26. Quigley HA, Cone FE. Development of diagnostic and treatment strategies for glaucoma through understanding and modification of scleral and lamina cribrosa connective tissue. Cell Tissue Res. 2013; 353:231-44. doi: 10.1007/s00441-013-1603-0 PMID: 23535950
27. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med. 2011; 3:82ra37. doi: 10.1126/scitranslmed.3002227 PMID: 21562229
28. Gross ND, Kempton JB, Trune DR. Spironolactone blocks glucocorticoid-mediated hearing preservation in autoimmune mice. Laryngoscope. 2002; 112:298-303. PMID: 11889387
29. Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, et al. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation. 2011; 124:582-588. doi: 10.1161/CIRCULATIONAHA.111.031716 PMID: 21768542
30. Pease ME, Hammond J, Quigley HA. Manometric calibration and comparison of TonoLab and Tono- Pen tonometers in rats with experimental glaucoma and in normal mice. J Glaucoma. 2006; 15:512-519, PMID: 17106364
31. Pease ME, Cone FE, Gelman S, Son JL, Quigley HA. Calibration of the TonoLab tonometer in mice with spontaneous or experimental glaucoma. Invest Ophthalmol Vis Sci. 2011; 52: 858-864. doi: 10. 1167/iovs.10-5556 PMID: 20720229
32. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995; 25:1111-1115. PMID: 7737724
33. Sachetelli S, Liu Q, Zhang SL, Liu F, Hsieh TJ, Brezniceanu ML, et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney International. 2006; 69:1016-1023. PMID: 16528251
34. Benicky J, Hafko R, Sanchez-Lemus E, Aguilera G, Saavedra JM. Six commercially available angiotensin II AT1 receptor antibodies are non-specific. Cell Mol Neurobiol. 2012; 32:1353-65. doi: 10.1007/s10571-012-9862-y PMID: 22843099
35. Harada K, Matsuoka H, Fujimoto N, Endo Y, Hasegawa Y, Matsuo A, et al. Localization of Type-2 Angiotensin II Receptor in Adrenal Gland. J Histochem Cytochem. 2010; 58: 585-593. doi: 10.1369/jhc.2010.955575 PMID: 20231739
36. Welsbie DS, Yang Z, Ge Y, Mitchell KL, Zhou X, Martin SE, et al. Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci U S A. 2013; 110:4045-50. doi: 10.1073/pnas.1211284110 PMID: 23431148
37. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure and primary open-angle glaucoma: a population-based assessment. Arch Ophthalmol. 1995; 113:216-21. PMID: 7864755
38. Downie LE, Vessey K, Miller A, Ward MM, Pianta MJ, Vingrys AJ, et al. Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience. 2009; 161:195-213. doi: 10.1016/j.neuroscience.2009.02.084 PMID: 19298848
39. Senanayake P, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci. 2007; 48:3301-11. PMID: 17591902
40. Savaskan E, Löffler KU, Meier F, Müller-Spahn F, Flammer J, Meyer P. Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res. 2004; 36:312-20. PMID: 15627831
41. Ferrari-Dileo G, Davis EB, Anderson DR. Angiotensin II binding receptors in retinal and optic nerve head blood vessels. An autoradiographic approach. Invest Ophthalmol Vis Sci. 1991; 32:21-6. PMID: 1987102
42. Wheeler-Schilling TH, Kohler K, Sautter M, Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci. 1999; 11:3387-94. PMID: 10564346
43. Yasuda N, Miura S-I, Akazawa H, Tanaka T, Qin Y, Kiya Y, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep. 2008; 90:179-186.
44. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011; 332:361-5. doi: 10.1126/science.1192152 PMID: 21493863
45. Shi H, Zhang Y-Y, Fu S-H, Lu Z-Z, Ye W, Xiao Y-Q. Angiotensin II as a morphogenic cytokine stimulating fibrogenesis of human Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci. 2015; 56:855-64. doi: 10.1167/iovs.14-15301 PMID: 25564450
46. Pan HW, Cui YH, Zeng JW. NF-κB mediates the survival of corneal myofibroblast induced by angiotensin II. Invest Ophthalmol Vis Sci. 2014; 55:4220-8. doi: 10.1167/iovs.13-13735 PMID: 24917146
47. Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol. 1996; 80:159-63. PMID: 8814748
48. Berka JL, Stubbs AJ, Wang DZ, DiNicolantonio R, Alcorn D, Campbell DJ, et al. Renin-containing Muller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci 1995; 36:1450-1458. PMID: 7775123
49. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003; 163:879-887. PMID: 12937129
50. Senanayake P, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci 2007; 48:3301-3311. PMID: 17591902
51. Downie LE, Vessey K, Miller A, Ward MM, Pianta MJ, Vingrys AJ, et al. Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience 2009; 161:195-213. doi: 10.1016/j.neuroscience.2009.02.084 PMID: 19298848
52. Milenkovic VM, Brockmann M, Meyer C, Desch M, Schweda F, Kurtz A, et al. Regulation of the renin expression in the retinal pigment epithelium by systemic stimuli. Am J Physiol Renal Physiol 2010; 299: F396-F403. doi: 10.1152/ajprenal.00576.2009 PMID: 20519377
53. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res. 2010; 29:284-311. doi: 10.1016/j.preteyeres.2010.03.003 PMID: 20380890
54. Sossi N, Anderson DR. Blockage of axonal transport in optic nerve induced by elevation of intraocular pressure. Effect of arterial hypertension induced by angiotensin I. Arch Ophthalmol. 1983; 101:94-7. PMID: 6185108
55. Meyer P, Flammer J, Lüscher TF. Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists. Invest Ophthalmol Vis Sci. 1995; 36:555-62. PMID: 7890486
56. Moltzer E, Essers J, van Esch JH, Roos-Hesselink JW, Danser AH. The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications. Pharmacol Ther. 2011; 131:50-60. doi: 10. 1016/j.pharmthera.2011.04.002 PMID: 21504760
57. Wilkinson-Berka JL, Tan G, Jaworski K, Ninkovic S. Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am J Hypertens. 2007; 20:423-430. PMID: 17386351
58. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009; 361:40-51. doi: 10.1056/NEJMoa0808400 PMID: 19571282
59. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension. 2000; 36:1099-1104. PMID: 11116132
60. Nagai N, Noda K, Urano T, Kubota Y, Shinoda H, Koto T, et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005; 46:1078-1084. PMID: 15728568
61. Downie LE, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy. Glia 2008; 56:1076-1090. doi: 10.1002/glia.20680 PMID: 18442090
62. Nagai N, Oike Y, Izumi-Nagai K, Koto T, Satofuka S, Shinoda H, et al. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest Ophthalmol Vis Sci 2007; 48:2321-2326. PMID: 17460297
63. Striker GE, Praddaude F, Alcazar O, Cousins SW, Marin-Castano ME. Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II. Am J Physiol Cell Physiol. 2008; 295:C1633-C1646. doi: 10.1152/ajpcell.00092.2008 PMID: 18923060
64. Praddaude F, Cousins SW, Pecher C, Marin-Castano ME. Angiotensin II induced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium. Exp Eye Res 2009; 89:109-118. doi: 10.1016/j.exer.2009.02.020 PMID: 19281810
65. Shi H, Zhang Y, Fu S, Lu Z, Ye W, Xiao Y. Angiotensin II as a morphogenic cytokine stimulating fibrogenesis of human Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci. 2015; 56:855-864. doi: 10. 1167/iovs.14-15301 PMID: 25564450
66. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension.1994; 23:587-92. PMID: 8175166
67. Wolf G, Ziyadeh FN, Stahl RA. Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med. 1999; 77:556-64. PMID: 10494801
68. Fukuda N, Hu WY, Kubo A, Kishioka H, Satoh C, Soma M, et al. Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells. Am J Hypertens. 2000; 13:191-8 PMID: 10701820
69. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin- 1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am. J. Physiol. Renal Physiol 2004; 286:F278-87. PMID: 14583433
70. Bull ND, Johnson TV, Welsapar G, DeKorver NW, Tomarev SI, Martin KR. Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Invest Ophthalmol Vis Sci. 2011; 52:3309-20. doi: 10.1167/iovs.10-6873 PMID: 21345987
71. White AJ, Heller JP, Leung J, Tassoni A, Martin KR. Retinal ganglion cell neuroprotection by an angiotensin II blocker in an ex vivo retinal explant model. J Renin Angiotensin Aldosterone Syst. 2015 Jan 26, pii: 1470320314566018.
72. Lv B, Wang R, Gao X, Dong X, Ji X. Effect of vascular endothelial growth factor on retinal ganglion cells of rats with chronic intraocular hypertension. Int J Clin Exp Pathol. 2014; 7:5717-24. PMID: 25337213
73. Park HY, Kim JH, Park CK. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol. 2014; 184:1752-62. doi: 10.1016/j. ajpath.2014.02.016 PMID: 24709590
74. Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013; 182:1379-90. doi: 10.1016/j.ajpath.2012.12.032 PMID: 23416159
75. Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension. 2004; 43:276-81. PMID: 14718351
76. Hatzopoulos KM, Vessey KA, Wilkinson-Berka JL, Fletcher EL. The vasoneuronal effects of AT1 receptor blockade in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2014; 55:3957-70. doi: 10.1167/iovs.13-13532 PMID: 24894399
77. De Groef L, Van Hove I, Dekeyster E, Stalmans I, Moons L. MMPs in the neuroretina and optic nerve: modulators of glaucoma pathogenesis and repair? Invest Ophthalmol Vis Sci. 2014; 55:1953-64. doi: 10.1167/iovs.13-13630 PMID: 24681977
78. Agarwal R, Krasilnikova AV, Raja IS, Agarwal P, Mohd Ismail N. Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats. Eur J Pharmacol. 2014; 730:8-13. doi: 10.1016/j.ejphar.2014.02.021 PMID: 24583339
79. Wang RF, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2005; 80:629-32. PMID: 15862169
80. Costagliola C, Verolino M, De Rosa ML, Iaccarino G, Ciancaglini M, Mastropasqua L. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Exp Eye Res. 2000; 71:167-71. PMID: 10930321
81. Matulla B, Streit G, Pieh S, Findl O, Entlicher J, Graselli U, et al. Effects of losartan on cerebral and ocular circulation in healthy subjects. Br J Clin Pharmacol. 1997; 44:369-75. PMID: 9354312
82. Guo F, Sun Y, Su L, Li S, Liu Z, Li J, et al. Losartan attenuates paraquat-induced pulmonary fibrosis in rats. Hum Exp Toxicol. 2015; 34:497-505. doi: 10.1177/0960327114543840 PMID: 25233898